Cargando…

Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom

OBJECTIVE: To estimate the cost-effectiveness of adding a selective phosphodiesterase-4 inhibitor, roflumilast, to a long-acting bronchodilator therapy (LABA) for the treatment of patients with severe-to-very severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Samyshkin, Yevgeniy, Kotchie, Robert W., Mörk, Ann-Christin, Briggs, Andrew H., Bateman, Eric D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2013
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889819/ https://www.ncbi.nlm.nih.gov/pubmed/23392624 http://dx.doi.org/10.1007/s10198-013-0456-5

Ejemplares similares

Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland
por: Samyshkin, Yevgeniy, et al.
Publicado: (2013)

Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis
por: Hertel, Nadine, et al.
Publicado: (2012)

Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy vs triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK
por: Kiff, Chris, et al.
Publicado: (2018)

Roflumilast: a review of its use in the treatment of COPD
por: Wedzicha, Jadwiga A, et al.
Publicado: (2016)

Pharmacological mechanism of roflumilast in the treatment of asthma–COPD overlap
por: Zhang, Xiaoli, et al.
Publicado: (2018)

Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
por: Donohue, James F, et al.
Publicado: (2019)

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD
por: Giembycz, Mark A, et al.
Publicado: (2010)

Cost-Effectiveness of Dual Bronchodilator Indacaterol/Glycopyrronium for COPD Treatment in China
por: Gong, Shiyi, et al.
Publicado: (2021)

Roflumilast in COPD: a Brazilian perspective
por: Stirbulov, Roberto, et al.
Publicado: (2015)

The role of bronchodilator treatment in the prevention of exacerbations of COPD
por: Wedzicha, Jadwiga A., et al.
Publicado: (2012)

Vulnerable COPD patients with comorbidities: the role of roflumilast
por: Lipari, Melissa, et al.
Publicado: (2014)

Efficacy and Safety of Roflumilast in Korean Patients with COPD
por: Lee, Jae Seung, et al.
Publicado: (2016)

PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast
por: Boswell-Smith, Victoria, et al.
Publicado: (2007)

Which bronchodilator in COPD?
por: Russell, Richard, et al.
Publicado: (2007)

COPD: maximization of bronchodilation
por: Nardini, Stefano, et al.
Publicado: (2014)

Predicting treatable traits for long-acting bronchodilators in patients with stable COPD
por: Kang, Jieun, et al.
Publicado: (2017)

Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement
por: Vogelmeier, Claus F, et al.
Publicado: (2021)

Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis
por: Yuan, Lianfang, et al.
Publicado: (2016)

A Way to Increase the Bioaccesibility and Photostability of Roflumilast, a COPD Treatment, by Cyclodextrin Monomers
por: Matencio, Adrián, et al.
Publicado: (2019)

The Role of the Pharmacist in Optimizing Outcomes With Roflumilast, a PDE4 Inhibitor for the Treatment of COPD
por: Williams, Dennis
Publicado: (2020)

New therapeutic options in the management of COPD – focus on roflumilast
por: Antoniu, Sabina Antonela
Publicado: (2011)

Does roflumilast induce phagocytic activity in COPD patients?
por: Ghosh, Baishakhi, et al.
Publicado: (2015)

Is it Reasonable to Start Bronchodilator Treatment Before Confirming the Diagnosis of COPD?
por: Figueira-Gonçalves, Juan Marco, et al.
Publicado: (2023)

Severe COPD Exacerbation Risk and Long-Acting Bronchodilator Treatments: Comparison of Three Observational Data Analysis Methods
por: Roberts, Melissa H., et al.
Publicado: (2015)

Bronchodilators use in patients with COPD
por: Dong, Yaa-Hui, et al.
Publicado: (2015)

Short Term Effects of Tiotropium on COPD Patients Treated with Long Acting Bronchodilators
por: Nicolini, Antonello
Publicado: (2012)

Comparative efficacy of long-acting bronchodilators for COPD - a network meta-analysis
por: Cope, Shannon, et al.
Publicado: (2013)

Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol
por: Matera, Maria Gabriella, et al.
Publicado: (2015)

Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives
por: Rhee, Chin Kook, et al.
Publicado: (2019)

Establishing Quality of Life in Southern Taiwan COPD Patients Using Long-Acting Bronchodilator
por: Chin, Pik-Qi, et al.
Publicado: (2022)

Therapeutic Success in Swiss COPD Patients Receiving Dual Bronchodilation Therapy as COPD Maintenance Treatment
por: Spielmanns, Marc, et al.
Publicado: (2022)

Optimizing bronchodilation in the prevention of COPD exacerbations
por: Miravitlles, Marc, et al.
Publicado: (2017)

When is dual bronchodilation indicated in COPD?
por: Thomas, Mike, et al.
Publicado: (2017)

Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care
por: Punekar, Yogesh Suresh, et al.
Publicado: (2015)

Adherence to roflumilast under dose-escalation strategy in Korean patients with COPD
por: Park, Tai Sun, et al.
Publicado: (2019)

Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population
por: Moll, Keran, et al.
Publicado: (2015)

A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD
por: Jara, Michele, et al.
Publicado: (2012)

Long-acting bronchodilators with or without inhaled corticosteroids and 30-day readmission in patients hospitalized for COPD
por: Bishwakarma, Raju, et al.
Publicado: (2017)

Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy
por: Halpin, David M. G., et al.
Publicado: (2016)

Optimal Bronchodilation for COPD Patients: Are All Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonists the Same?
por: Miravitlles, Marc, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7nnk0022i71m9cpobjap1vbnf8